Biblio
Alteration of Naïve and Memory B-Cell Subset in Chronic Graft-Versus-Host Disease Patients After Treatment With Mesenchymal Stromal Cells. Stem Cells Transl Med. 2014.
A gut microbiota score predicting for acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation. Am J Transplant. 2019.
Haplo-peripheral blood stem cell plus cord blood grafts for hematologic malignancies might lead to lower relapse compared with haplo-peripheral blood stem cell plus bone marrow grafts. Transplant Cell Ther. 2022.
Herpesvirus-Associated Central Nervous System Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. PLoS One. 2013;8(10):e77805.
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. Signal Transduct Target Ther. 2023;8(1):348.
Intestinal microbiota can predict aGVHD following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. Oncoimmunology. 2016;5(5):e1139274.
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023.
Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT. Biol Blood Marrow Transplant. 2019.